Orna Therapeutics, through its wholly owned subsidiary ReNAgade Therapeutics, has entered a three-year strategic research collaboration with Vertex Pharmaceuticals to utilize Orna’s novel and...
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for GSK's GSK5764227 (GSK’227), its B7-H3-targeted antibody-drug conjugate (ADC) being evaluated for...
Araris, a Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs), has entered a Research Collaboration and Option to License Agreement (RCO) under...